Research Analysts Set Expectations for XFOR Q1 Earnings

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) – Stock analysts at Brookline Cap M issued their Q1 2026 earnings per share estimates for shares of X4 Pharmaceuticals in a research report issued on Tuesday, March 17th. Brookline Cap M analyst L. Cann forecasts that the company will post earnings per share of ($0.20) for the quarter. The consensus estimate for X4 Pharmaceuticals’ current full-year earnings is ($0.68) per share. Brookline Cap M also issued estimates for X4 Pharmaceuticals’ Q2 2026 earnings at ($0.23) EPS and FY2030 earnings at $2.85 EPS.

Other analysts have also recently issued research reports about the stock. Wall Street Zen cut shares of X4 Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Sunday, November 30th. Guggenheim initiated coverage on X4 Pharmaceuticals in a report on Monday, March 9th. They issued a “buy” rating and a $12.00 price objective on the stock. Stifel Nicolaus set a $10.00 price objective on X4 Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, December 5th. Zacks Research cut X4 Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, November 26th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of X4 Pharmaceuticals in a research report on Monday, December 29th. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $28.88.

X4 Pharmaceuticals Price Performance

Shares of XFOR stock opened at $4.05 on Thursday. The company has a debt-to-equity ratio of 1.23, a current ratio of 5.65 and a quick ratio of 5.48. The firm’s 50-day moving average is $3.66 and its two-hundred day moving average is $3.62. X4 Pharmaceuticals has a 12 month low of $1.35 and a 12 month high of $9.56. The company has a market capitalization of $354.13 million, a PE ratio of -0.93 and a beta of 0.43.

X4 Pharmaceuticals (NASDAQ:XFOR) last announced its quarterly earnings results on Tuesday, March 24th. The company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.36) by $0.14. X4 Pharmaceuticals had a negative net margin of 225.55% and a negative return on equity of 268.37%. The firm had revenue of $2.57 million for the quarter, compared to analysts’ expectations of $1.68 million.

Hedge Funds Weigh In On X4 Pharmaceuticals

Several large investors have recently made changes to their positions in the stock. Indivisible Partners acquired a new stake in X4 Pharmaceuticals in the 4th quarter valued at approximately $40,000. Rhumbline Advisers lifted its stake in X4 Pharmaceuticals by 5.4% during the first quarter. Rhumbline Advisers now owns 188,415 shares of the company’s stock worth $44,000 after purchasing an additional 9,690 shares in the last quarter. Two Sigma Investments LP acquired a new position in X4 Pharmaceuticals during the third quarter worth $47,000. Squarepoint Ops LLC purchased a new position in shares of X4 Pharmaceuticals during the fourth quarter worth $50,000. Finally, Stifel Financial Corp purchased a new position in shares of X4 Pharmaceuticals during the fourth quarter worth $82,000. 72.03% of the stock is currently owned by institutional investors and hedge funds.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.